2024
Focal and Developing Asymmetries
Tamayo S, Andrejeva L, Singh K. Focal and Developing Asymmetries. 2024, 159-184. DOI: 10.1007/978-3-031-65711-5_6.Peer-Reviewed Original ResearchFocal asymmetryBreast cancerBreast tissueBenign breast tissueFibroglandular tissue densityLikelihood of malignancyComparison mammogramsFibroadenomatoid changeMalignant causesBaseline mammogramMammographic findingsBenign causesSonographic abnormalitiesNon-palpableFat necrosisImaging findingsScreening mammographyArchitectural distortionPosttreatment changesMammographic viewsBreastMalignancyTissue densityCancerMammograms
2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohort
2020
Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer
Maliniak M, Cheriyan A, Sherman M, Liu Y, Gogineni K, Liu J, He J, Krishnamurti U, Miller-Kleinhenz J, Ashiqueali R, He J, Yacoub R, McCullough L. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Research 2020, 22: 65. PMID: 32552729, PMCID: PMC7298873, DOI: 10.1186/s13058-020-01308-4.Peer-Reviewed Original ResearchConceptsBreast adipose tissueHazard ratioBreast cancerAdipose tissueMultivariable Cox proportional hazards modelsWhite womenCox proportional hazards modelProgression-free survivalMedical record reviewCurrent smoking statusConfidence intervalsProportional hazards modelBenign breast tissueBreast cancer prognosisNon-tumor tissuesCrown-like structuresMulti-racial populationEvidence of associationWorse OSWhite patientsClinical outcomesRecord reviewSmoking statusLifestyle factorsMultivariable model
2008
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum
Chung G, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum. 2008 DOI: 10.21236/ada487987.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeWhole section analysisBenign breast tissueHeterogeneity of expressionSSTR2 levelsProgression of cancerTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceLymphatic elementsCo-localization techniquesCell line controlMalignant cellsSSTR2Breast tissueCancerPattern of expressionProtein expressionPeptide hormonesVessel compartmentReference standard curveSomatostatin
2006
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy With 111-in-Penetreotide. 2006 DOI: 10.21236/ada455786.Peer-Reviewed Original ResearchBreast cancerTissue microarrayPredominant receptor subtypeBenign breast tissueSSTR2 levelsProgression of cancerSSTR2 expressionBone tumorsTargeted therapyReceptor subtypesSomatostatin receptorsClinical significanceCo-localization techniquesCell line controlMalignant cellsCancerBreast tissuePattern of expressionProtein expressionPeptide hormonesSomatostatinSSTR2ExpressionLarge proportionTherapy
2005
Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide. 2005 DOI: 10.21236/ada436873.Peer-Reviewed Original ResearchBreast cancerTissue microarraySSTR2 expressionClinical trialsPredominant receptor subtypeRadiolabelled SST analoguesMetastatic breast cancerRadiolabelled somatostatin analoguesMalignant breast epitheliumResponse/survivalBenign breast tissueCell lines expressionProgression of cancerSST analogsSomatostatin analoguesTargeted therapyReceptor subtypesSomatostatin receptorsBreast epitheliumCo-localization techniquesCancerBreast tissueSSTR2Protein expressionPeptide hormones
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply